Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level

Nat Med. 2010 Sep;16(9):995-7. doi: 10.1038/nm.2203. Epub 2010 Aug 29.

Abstract

By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit. The enhanced neutralization resistance of HIV-1 in contemporary seroconverters coincided with the poorer elicitation of neutralizing antibody responses, which may have implications for vaccine design.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • AIDS Vaccines / therapeutic use
  • Antibody Formation / immunology
  • Genetic Variation
  • HIV / genetics
  • HIV / immunology
  • HIV Antibodies / immunology*
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / immunology*
  • HIV Infections / immunology*
  • Humans
  • Immunity, Humoral
  • Immunoglobulins, Intravenous / immunology
  • Immunoglobulins, Intravenous / therapeutic use
  • Neutralization Tests
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology
  • Viral Envelope Proteins / metabolism

Substances

  • AIDS Vaccines
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV hyperimmune globulin
  • Immunoglobulins, Intravenous
  • Viral Envelope Proteins
  • gp120 protein, Human immunodeficiency virus 1